Key facts
- This page summarizes Kaupinen Wes's Form 4/A - Amendment filing for PALVELLA THERAPEUTICS, INC. (PVLA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Feb 2025, 18:25.
Kaupinen Wes - 05 Feb 2025 Form 4/A - Amendment Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- PVLA
- Reported as of
- 05 Feb 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 10 Feb 2025, 18:25:31 UTC
- Original report date
- 07 Feb 2025
- Prior SEC filing
- 06 Jan 2025
- Next SEC filing
- 09 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Kathleen A. McGowan For: Wes Kaupinen
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Kaupinen Wes filed Form 4/A - Amendment for PALVELLA THERAPEUTICS, INC. (PVLA) on 10 Feb 2025.
Change
- Previous filing in this sequence was filed on 06 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVLA
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +243,831
- Change %
- Price
- $0.000000
- Shares after
- 243,831
- Date
- 05 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 243,831
- Exercise price
- $14.76
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock options will vest in equal monthly tranches over 48 months
SEC remarks
This amendment is being filed to reflect a change in the reporting person's name from Palvella Therapeutics, Inc to Wes Kaupinen.